A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 12,74 (+52,39%). A mediana é € 12,74 (+52,39%).
| Comprar |
7 |
| Manter |
0 |
| Vender |
0 |
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
908 Devices focuses on handheld detection devices and strengthens financial profile
908 Devices announces a strategic focus on handheld chemical detectors intended to drive faster growth, improved margins and reduced cash burn. Revenue rose 23% in Q2 2026 to $16.1m, adjusted EBITDA loss for the quarter fell to below $2m, and the company reports $101.5m in cash with no debt. The 2026 revenue guidance was raised to $68–70m; recurring revenue is around 30% and is expected to grow further through the acquisition of NIRLab. 908 Devices highlights large market opportunities (opioid crisis, defense, border security) and an installed base of more than 4,100 devices with 700 customers in over 70 countries. » Mais em de.investing.com
908 Devices reports 23% revenue growth in Q2 2026 and halves adjusted EBITDA loss
908 Devices posted Q2 2026 revenue of $16.1 million, up 23% year‑over‑year, driven by FTIR product shipments and U.S. state and local demand. Adjusted EBITDA loss narrowed to about $1.9 million, a roughly 50% improvement, while adjusted gross margin rose to ~57%. The company closed the NIRLAB acquisition, sold 35+ NIRLAB units with multiyear subscriptions, and secured a $6 million ProtectIR order for APAC. Cash and equivalents were $101.5 million with no debt, and full‑year revenue guidance was raised to $68–70 million, excluding potential AVCAD program upside. » Mais em finance.yahoo.com
908 Devices focuses on handheld detection devices and reports solid financials
At the Growth Conference, 908 Devices presented a strategic shift away from medical technology toward handheld mass spectrometers for defense, law enforcement and public safety. The company has more than USD 100 million in liquidity and an adjusted EBITDA in the mid-single-digit millions, providing several years of financial runway. The product range spans the low-cost NIRLab to the flagship MX908; a new, more compact MX908 generation is planned for late 2026. Government grant programs and military projects such as AVCAD, together with growing international demand, are cited as the main growth drivers. » Mais em de.investing.com
908 Devices accelerates transformation despite missed earnings expectation
908 Devices reported Q1 2026 revenue of $13.4 million (+14% y/y) and improved adjusted gross margin (57%) as well as adjusted EBITDA (-$2.5 million). EPS of -$0.32 missed estimates mainly due to a $6.4 million contingent consideration from acquisitions, while GAAP losses persist. The balance sheet is debt-free with $112 million in cash; the company is growing its installed base and recurring revenues, and the new VipIR device is expected to drive growth in 2026. For 2026, 908 Devices forecasts revenue of $67–70 million and an improvement in adjusted EBITDA to the mid-single-digit millions, but remains dependent on integration costs and the conversion to sustainable GAAP profitability. » Mais em de.investing.com
908 Devices appoints Kola Otitoju as chief business & strategy officer
908 Devices has appointed Kola Otitoju to the newly created role of chief business & strategy officer; he will drive product and corporate strategy, business development, M&A and partnerships. Otitoju brings more than 25 years of experience in strategy, business development and P&L management, most recently serving as senior vice president at Repligen Corporation. The board granted him 110,193 RSUs and options on 146,789 common shares with an exercise price of $7.26; both awards vest over three years. The appointment comes after the stock rose 52% over the past year, though the company still reports a loss of $0.93 per share; the balance sheet is viewed as well capitalized/liquid. » Mais em de.investing.com
Dividendos históricos Dividendos
Todos os indicadores de dividendos Todos os indicadoresDados financeiros da empresa
| (EUR) | setembro de 2026 | YoY |
|---|---|---|
| Receitas | 16,73 mi | 40,19% |
| Ganho bruto | 8,84 mi | 50,43% |
| Ganho líquido | -4,04 mi | 68,18% |
| EBITDA | -4,09 mi | 65,22% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 368,45 mi |
Número de ações | 41,58 mi |
Máximo/mínimo de 52 semanas | € 12,14 - € 4,57 |
| Dividendos | Não |
Beta | 0,63 |
PER (PE Ratio) | -15,46 |
PEG (PEG Ratio) | 0,01 |
P/VC (PB Ratio) | 2,67 |
P/V (PS Ratio) | 6,16 |
Perfil da empresa
A 908 Devices Inc., uma empresa de tecnologia em fase comercial, fornece vários dispositivos de espectrometria de massa (Mass Spec) portáteis e de secretária, concebidos para fins específicos, para analisar materiais desconhecidos e invisíveis na investigação em ciências da vida, bioprocessamento, biotecnologia industrial, medicina forense e mercados adjacentes. Os produtos da empresa incluem o MX908, um dispositivo de espectrometria de massa portátil, alimentado por bateria, concebido para a análise rápida de materiais gasosos, líquidos e sólidos de identidade desconhecida; o Rebel, um pequeno analisador de secretária que fornece informações em tempo real sobre o ambiente extracelular em bioprocessos; e a solução ZipChip, uma plataforma de separação de alta resolução, plug-and-play, que otimiza a análise de amostras por Mass Spec. A empresa opera nas Américas, na Europa, no Médio Oriente, em África e na Ásia-Pacífico. A empresa foi constituída em 2012 e tem sede em Boston, Massachusetts.
| Nome | 908 DEVICES INC. DL-,001 |
| CEO | Kevin J. Knopp |
| Sede | Burlington,
ma Japão |
| Site | |
| Setor | Serviços públicos |
| Indústria | Equipamentos e serviços de energia |
| Entrada em bolsa | 18/03/2010 |
| Colaboradores | 172 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | MASS |